Table 1

Trials data set included in final analysis

Study	Publication year	Primary end-point mortality	Power (%)	Sample size calculation	Anticipated control arm mortality (%)	Estimated absolute effect Size (%)	Control arm (n)	Intervention arm (n)	Control arm mortality (with 95% CI)	Intervention arm mortality (with 95% CI)	Control—intervention (with 95% CI)
SBITS18	2007	28	90	800	30	10	303	321	37.3 (31.9 to 42.7)	39.3 (34.0 to 44.6)	−2.0 (–9.6 to 5.6)
VASST19	2008	28	80	776	60	10	382	396	39.3 (34.4 to 44.2)	37.4 (32.6 to 42.2)	1.9 (–4.9 to 8.7)
CORTICUS20	2008	28	80	800	50	10	248	251	31.5 (25.7 to 37.3)	34.3 (28.4 to 40.2)	−2.8 (–11.0 to 5.4)
COIITS21	2010	In-hospital	80	508	50	12.5	254	255	42.9 (36.8 to 49.0)	45.9 (39.8 to 52.0)	−3.0 (–11.6 to 5.6)
PROWESS-SHOCK22	2012	28	80	1500*	35	7	834	846	24.2 (21.3 to 27.1)	26.4 (23.4 to 29.4)	−2.2 (–6.4 to 2.0)
6S23	2012	90	80	800	45	10	400	398	43.0 (38.1 to 47.9)	51.0 (46.1 to 55.9)	−8.0 (–14.9 too 1.1)
ACCESS24	2013	28	90	2000	40	7.5	657	1304	26.9 (23.5 to 30.3)	28.1 (25.7 to 30.5)	−1.2 (–5.4 to 3.0)
TRISS25	2014	90	80	1000	45	9	502	496	45.0 (40.6 to 49.4)	43.0 (38.6 to 47.4)	2.0 (–4.2 to 8.2)
ProCESS26	2014	60	80	1950*	38	6.5†	456	885	18.9 (15.3 to 22.5)	21.0 (18.3 to 23.7)	−2.1 (–6.6 to 2.4)
ARISE11	2014	90	87.5†	1600	28	7.6	804	796	18.8 (16.1 to 21.5)	18.6 (15.9 to 21.3)	0.2 (–3.6 to 4.0)
SEPSISPAM27	2014	28	80	800	45	10	388	388	34.0 (29.3 to 38.7)	36.6 (31.8 to 41.4)	−2.6 (–9.3 to 4.1)
ALBIOS9	2014	28	80	1350	45	7.5	900	895	32.0 (29.0 to 35.0)	31.8 (28.7 to 34.9)	0.2 (–4.1 to 4.5)
ProMISe28	2015	90	80	1260	40	8	630	630	29.2 (25.6 to 32.8)	29.5 (25.9 to 33.1)	−0.3 (–5.3 to 4.7)